Dong-A ST, 1Q Sales 153.5 Billion KRW... Operating Profit 7.9 Billion KRW

Published 27 Apr.2022 16:06(KST)

[Asia Economy Reporter Chunhee Lee] Dong-A ST announced on the 27th that its preliminary operating results for the first quarter of this year showed sales of 153.516 billion KRW and operating profit of 7.887 billion KRW. These figures represent increases of 9.0% and 820.1%, respectively, compared to the same period last year.

By segment, the prescription drug (ETC) division achieved sales of 94.3 billion KRW, up 10.4% year-on-year, driven by increased sales of key products such as Suganon, Motilitone, and Grotropin.

The overseas export division recorded sales of 37.4 billion KRW. Although sales in the bio and anti-tuberculosis sectors declined due to geopolitical factors, sales of canned Bacchus (Cambodia) increased by 22.2% year-on-year, resulting in an overall 2.5% increase compared to the same period last year. The company stated, "We expect sales growth of Croserin/Clopazimine when the World Health Organization (WHO) tender market opens later this year," and added, "We also anticipate sales expansion by entering the Brazilian Grotropin tender market."

The medical devices and diagnostics division saw a 15.2% year-on-year growth to 16.6 billion KRW in sales, driven by increased sales of medical equipment and expanded sales in the infection control sector of diagnostics.

Operating profit surged by 820.1% due to overall sales growth and reduced selling and administrative expenses through efficient cost management. Net profit for the period also rose 209.7% year-on-year to 2.291 billion KRW.